Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Zevra Therapeutics's pe ratio was 12.7× on Nov 11, 2026, against 17.9× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.7× | −6.3 |
| 2025 | Dec 31, 2025 | 19.1× | – |
See a number that looks wrong?